ArticleAntibiotics (Basel, Switzerland)2022
Exploring the Antibiotic Resistance Profile of Clinical
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- Article
- Insights ofInternational journal of microbiology · 2026Article
- Hospital-Based Genomic Surveillance ofBiology · 2025Article
- Antimicrobial activity of cephamycins and β-lactam/β-lactamase inhibitors against ESBL-producing Escherichia coli and Klebsiella pneumoniae under standard and high bacterial inocula.Scientific reports · 2025Article
- Genetic diversity, drug resistance, and biofilm formation in Klebsiella pneumoniae associated with nosocomial infection in Pelotas, RS, Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Molecular characterization and genome sequencing of selected highly resistant clinical isolates ofHeliyon · 2025Article
- Multi-omics investigation reveals unique markers inFrontiers in microbiology · 2025Article
- CombatingFrontiers in cellular and infection microbiology · 2025Review
- Predicting Drug Resistance: The Use of Novel Inflammatory Markers in Identifying ESBL-ProducingJournal of inflammation research · 2025Article
- HPLC-PDA Analysis of Polyacetylene Glucosides fromPharmaceuticals (Basel, Switzerland) · 2024Article
- Resistance Pattern ofMedicina (Kaunas, Lithuania) · 2024Article
- Prevalence of Antimicrobial Resistance inMicroorganisms · 2024Article
- Molecular and bacteriological investigations for the co-existence CRISPR/Cas system and β-lactamases of types extended-spectrum and carbapenemases in Multidrug, extensive drug and Pandrug-ResistantSaudi journal of biological sciences · 2024Article
- Molecular epidemiology of carbapenem-resistant gram-negative bacilli in Ecuador.BMC infectious diseases · 2024Article
- Comprehensive Analysis of Virulence Genes, Antibiotic Resistance, Biofilm Formation, and Sequence Types in Clinical Isolates ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Article
- Antimicrobial Potential of Different Isolates ofBiomolecules · 2023Article
- Prevalence of Extended-Spectrum β-Lactamases in Multidrug-Resistant Klebsiella pneumoniae Isolates in Jordanian Hospitals.Journal of epidemiology and global health · 2023Article
- Inverse Association between the Existence of CRISPR/Cas Systems with Antibiotic Resistance, Extended Spectrum β-Lactamase and Carbapenemase Production in Multidrug, Extensive Drug and Pandrug-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Klebsiella pneumoniae infection in the paediatric population before and after the COVID-19 pandemic in Shenzhen, China.The Journal of infection · 2023Article
- Cumulative Antibiogram: A Rapid Method to Hinder Transmission of Resistant Bacteria to Oral Cavity of Newborn Babies.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
While antibiotic resistance is rising to dangerously high levels, resistance mechanisms are spreading globally among diverse bacterial species. The emergence of antibiotic-resistant Klebsiella pneumoniae, mainly due to the production of antibiotic-inactivating enzymes, is currently responsible for most treatment failures, threatening the effectiveness of classes of antibiotics used for decades. This study assessed the presence of genetic determinants of β-lactam resistance in 102 multi-drug resistant (MDR) K. pneumoniae isolates from patients admitted to two central hospitals in northern Portugal from 2010 to 2020. Antimicrobial susceptibility testing revealed a high rate (>90%) of resistance to most β-lactam antibiotics, except for carbapenems and cephamycins, which showed antimicrobial susceptibility rates in the range of 23.5−34.3% and 40.2−68.6%, respectively. A diverse pool of β-lactam resistance genetic determinants, including carbapenemases- (i.e., blaKPC-like and blaOXA-48-like), extended-spectrum β-lactamases (ESBL; i.e., blaTEM-like, blaCTX-M-like and blaSHV-like), and AmpC β-lactamases-coding genes (i.e., blaCMY-2-like and blaDHA-like) were found in most K. pneumoniae isolates. blaKPC-like (72.5%) and ESBL genes (37.3−74.5%) were the most detected, with approximately 80% of K. pneumoniae isolates presenting two or more resistance genes. As the optimal treatment of β-lactamase-producing K. pneumoniae infections remains problematic, the high co-occurrence of multiple β-lactam resistance genes must be seen as a serious warning of the problem of antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.